Core Insights - Haichen Pharmaceutical (300584.SZ) reported a total revenue of 309 million yuan for the first half of 2025, an increase of 72.04 million yuan or 30.46% compared to the same period last year [1] - The net profit attributable to shareholders reached 29.16 million yuan, up by 4.42 million yuan or 17.87% year-on-year, marking three consecutive years of growth [1] - The net cash inflow from operating activities was 65.64 million yuan, an increase of 29.01 million yuan or 79.18% year-on-year, also achieving three consecutive years of growth [1] Financial Performance - The latest debt-to-asset ratio stands at 28.88%, a decrease of 0.47 percentage points from the same period last year [3] - The gross profit margin is reported at 85.88%, an increase of 1.74 percentage points year-on-year, continuing a three-year upward trend [3] - Return on equity (ROE) is at 2.80%, up by 0.35 percentage points compared to the previous year [3] Earnings and Ratios - The diluted earnings per share (EPS) is 0.24 yuan, an increase of 0.04 yuan or 17.90% year-on-year, marking three consecutive years of growth [3] - The total asset turnover ratio is 0.21 times, an increase of 0.04 times or 25.46% year-on-year [3] - The inventory turnover ratio is 0.53 times, up by 0.09 times or 21.32% year-on-year [3] Shareholder Structure - The number of shareholders is 26,000, with the top ten shareholders holding a total of 69.67 million shares, accounting for 58.06% of the total share capital [3] - The largest shareholder, Cao Yuping, holds 42.08% of the shares [3]

Core Insights - The company reported a total revenue of 309 million yuan and a net profit attributable to shareholders of 29.16 million yuan for the first half of 2025 [1] - The operating cash flow showed a net inflow of 65.64 million yuan [1] Financial Metrics - The latest debt-to-asset ratio is 28.88%, which is an increase of 0.07 percentage points from the previous quarter [3] - The gross profit margin is 85.88%, reflecting a decrease of 0.21 percentage points compared to the last quarter [3] - The return on equity (ROE) stands at 2.80% [3] - The diluted earnings per share (EPS) is 0.24 yuan [3] - The total asset turnover ratio is 0.21 times, while the inventory turnover ratio is 0.53 times [3] Shareholder Structure - The number of shareholders is 26,000, with the top ten shareholders holding a total of 69.67 million shares, accounting for 58.06% of the total share capital [3] - The largest shareholder, Cao Yuping, holds 42.08% of the shares [3] - Other notable shareholders include Jiang Xiaoqun (9.98%) and Liu Xiaoqian (2.86%) [3]

Core Insights - Hai Chen Pharmaceutical (300584.SZ) released its semi-annual report for 2025 on August 23, 2025, indicating a total of 6 institutional investors holding shares, amounting to 3.3137 million shares, which represents 2.76% of the total share capital [1] - The institutional investors include UBS AG, MORGAN STANLEY & CO. INTERNATIONAL PLC, Goldman Sachs International - proprietary funds, BARCLAYS BANK PLC, China International Capital Corporation, and J.P. Morgan Securities PLC - proprietary funds, with a total institutional holding ratio increase of 1.61 percentage points compared to the previous quarter [1] - In terms of foreign investment, there was no new disclosure of foreign institutions compared to the previous quarter, specifically mentioning MORGAN STANLEY & CO. INTERNATIONAL PLC [1]

（文章来源：证券日报） 证券日报网讯 8月22日晚间，海辰药业发布公告称，2025年半年度公司实现营业收入308，572，571.42 元，同比增长30.46%；归属于上市公司股东的净利润为29，157，742.41元，同比增长17.87%。 ...

Core Viewpoint - The company, Hai Chen Pharmaceutical, announced the approval of its 2025 semi-annual report and several other proposals during the second meeting of its fifth board of directors [2] Group 1 - The company held its fifth board of directors' second meeting on August 22 [2] - The meeting resulted in the approval of the full text and summary of the 2025 semi-annual report [2]

Group 1 - The company, Hai Chen Pharmaceutical, reported that as of August 20, the number of its shareholders was 20,339 [1]

Core Viewpoint - Haicheng Pharmaceutical (300584.SZ) reported a significant increase in revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential [1] Financial Performance - The company's operating revenue reached 309 million yuan, representing a year-on-year growth of 30.46% [1] - The net profit attributable to shareholders was 29.16 million yuan, showing a year-on-year increase of 17.87% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 28.85 million yuan, reflecting a year-on-year growth of 13.07% [1] - Basic earnings per share were reported at 0.243 yuan [1]

海辰药业8月22日晚间发布半年度业绩报告称，2025年上半年营业收入约3.09亿元，同比增加30.46%； 归属于上市公司股东的净利润约2916万元，同比增加17.87%；基本每股收益0.243元，同比增加17.9%。 （文章来源：每日经济新闻） ...

公司法定代表人： 曹于平 主管会计机构负责人： 陈建仁 会计机构负责人：李小卫 南京海辰药业股份有限公司 2025年1-6月非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | | | | | 单位：人民币万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的 | 2025年期初往来 | 2025年1-6月往来累 计发生金额（不含 | 2025年1-6月往 来资金的利息 | 2025年1-6月偿 | 2025年6月末往 | 占用形成原因 | 占用性质 | | | | 关联关系 | 会计科目 | 资金余额 | | | 还累计发生金额 | 来资金余额 | | | | | | | | | 利息） | （如有） | | | | | | 控股股东、实际控制人及其附属 | | | | | | | | | | | | 企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股 ...

证券代码：300584 证券简称：海辰药业 公告编号：2025-045 南京海辰药业股份有限公司 第五届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长曹于平先生召集，会议通知于 2025 年 8 月 19 日以 电话、电子邮件、专人送达等形式送达至各位董事，董事会会议通知中包括会议 的相关材料，同时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 8 月 22 日以通讯表决方式召开。 3、本次董事会应出席 7 人，实际出席会议人数为 7 人。 4、本次董事会由董事长曹于平先生主持，公司部分高级管理人员、证券部 工作人员列席了会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、董事会会议审议情况 会议审议并通过如下议案： 1、审议通过《2025 年半年度报告全文及其摘要》 公司董事会审议批准报出公司《2025 年半年度报告全文及其摘要》，具体内 容详见公司同日披露在中国证监会创业板指定信息披露网站巨潮资讯 ...